Search

Your search keyword '"Schaffar, Gregor"' showing total 18 results
Start Over Author "Schaffar, Gregor"
18 results on '"Schaffar, Gregor"'

4. A review of the totality of evidence supporting the development and approval of a pegfilgrastim biosimilar (LA-EP2006)

Author

Agarwala, Sanjiv S., primary, Nagl, CUlrich, additional, Guo, Xinghua, additional, Bellon, Anne, additional, Heyn, Jens, additional, Dimova-Dobreva, Miryana, additional, Shen, Yu-Ming, additional, Schaffar, Gregor, additional, Humphrey, Martin, additional, Mathieson, Nicola, additional, Koptelova, Natalia, additional, and Gattu, Sreekanth, additional

Published
2022
Full Text
View/download PDF

7. Recommendations for the Development and Validation of Immunogenicity Assays in Support of Biosimilar Programs.

Author

Civoli, Francesca, Kasinath, Aparna, Cai, Xiao-Yan, Wadhwa, Meenu, Exley, Andrew, Oldfield, Philip, Alvandkouhi, Safa, Schaffar, Gregor, Chappell, John, Bowsher, Ronald, Devanarayan, Viswanath, Marini, Joseph, Rebarchak, Shannon, Anderson, Michael, Koppenburg, Vera, and Lester, Todd

Abstract

For biosimilar drug development programs, it is essential to demonstrate that there are no clinically significant differences between the proposed biosimilar therapeutic (biosimilar) and its reference product (originator). Based on a stepwise comprehensive comparability exercise, the biosimilar must demonstrate similarity to the originator in physicochemical characteristics, biological activity, pharmacokinetics, efficacy, and safety, including immunogenicity. The goal of the immunogenicity assessment is to evaluate potential differences between the proposed biosimilar product and the originator product in the incidence and severity of human immune responses. Establishing that there are no clinically meaningful differences in the immune response between the products is a key element in the demonstration of biosimilarity. An issue of practical, regulatory, and financial importance is to establish whether a two-assay (based on the biosimilar and originator respectively) or a one-assay approach (based on the biosimilar) is optimal for the comparative immunogenicity assessment. This paper recommends the use of a single, biosimilar-based assay for assessing immunogenic similarity in support of biosimilar drug development. The development and validation of an ADA assay used for a biosimilar program should include all the assessments recommended for an innovator program (10–16, 29). In addition, specific parameters also need to be evaluated, to gain confidence that the assay can detect antibodies against both the biosimilar and the originator. Specifically, the biosimilar and the originator should be compared in antigenic equivalence, to assess the ability of the biosimilar and the originator to bind in a similar manner to the positive control(s), as well as in the confirmatory assay and drug tolerance experiments. Practical guidance for the development and validation of anti-drug antibody (ADA) assays to assess immunogenicity of a biosimilar in comparison to the originator, using the one-assay approach, are described herein. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

9. Evaluation of the safety and immunogenicity of subcutaneous HX575 epoetin alfa in the treatment of anemia associated with chronic kidney disease in predialysis and dialysis patients

Author

Casadevall, Nicole, primary, Dobronravov, Vladimir, additional, Eckardt, Kai-Uwe, additional, Ertürk, Sehsuvar, additional, Martynyuk, Liliya, additional, Schmitt, Susanne, additional, Schaffar, Gregor, additional, Rudy, Anita, additional, Krendyukov, Andriy, additional, and Ode, Marité, additional

Published
2017
Full Text
View/download PDF

10. A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease

Author

Weir, Matthew R., primary, Pergola, Pablo E., additional, Agarwal, Rajiv , additional, Fink, Jeffrey C., additional, Kopyt, Nelson P., additional, Singh, Ajay K., additional, Kumar, Jayant, additional, Schmitt, Susanne, additional, Schaffar, Gregor, additional, Rudy, Anita, additional, McKay, Jim P., additional, and Kanceva, Radmila, additional

Published
2017
Full Text
View/download PDF

12. A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial

Author

Blackwell, Kimberly, primary, Donskih, Roman, additional, Jones, C. Michael, additional, Nixon, Allen, additional, Vidal, Maria J., additional, Nakov, Roumen, additional, Singh, Pritibha, additional, Schaffar, Gregor, additional, Gascón, Pere, additional, and Harbeck, Nadia, additional

Published
2016
Full Text
View/download PDF

17. Cellular Toxicity of Polyglutamine Expansion Proteins

Author

Schaffar, Gregor, primary, Breuer, Peter, additional, Boteva, Raina, additional, Behrends, Christian, additional, Tzvetkov, Nikolay, additional, Strippel, Nadine, additional, Sakahira, Hideki, additional, Siegers, Katja, additional, Hayer-Hartl, Manajit, additional, and Hartl, F.Ulrich, additional

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results